GLP-1 pills: what the labels say about oral semaglutide and orforglipron
A GLP-1 pill is a tablet that swaps the weekly injection for a daily swallow. The tablets are not simply a pen in pill form: the labels give different rules for water, timing, food and absorption, and the semaglutide tablet doses are not interchangeable with the injected doses. This page lays out what the cached FDA labels say, and nothing beyond them.
- Oral semaglutide
- Once daily
- Empty stomach, up to 4 ounces of water (labels)
- Foundayo (orforglipron)
- Once daily
- With or without food (label)
- Oral semaglutide absorbed
- 0.4% to 2%
- Label estimates of absolute bioavailability
- Orforglipron absorbed
- 77%
- After a 0.8 mg dose (label)
Which GLP-1 pills carry an FDA label
Four labelled tablets are covered here. Rybelsus and Ozempic tablets share one label and are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for them. Wegovy tablets sit on the Wegovy label, which also covers the injection, and are indicated, with a reduced calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and to reduce excess body weight and maintain weight reduction long term in adults with obesity or with overweight plus a weight-related condition. Foundayo is the brand for orforglipron and is indicated, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction in adults with obesity, or with overweight plus at least one weight-related condition.
Semaglutide and orforglipron are both described on their labels as GLP-1 receptor agonists, but they are different molecules. The semaglutide tablets are co-formulated with SNAC, an absorption helper named on the label. The Foundayo label does not mention one and reports a far higher share absorbed, covered below.
| Product | Strengths | Dosing frequency |
|---|---|---|
| Rybelsus | 3 mg, 7 mg, 14 mg | Once daily |
| Ozempic tablets | 1.5 mg, 4 mg, 9 mg | Once daily |
| Wegovy tablets | 1.5 mg, 4 mg, 9 mg, 25 mg | Once daily |
| Foundayo | 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg | Once daily |
The semaglutide tablet rules
The Rybelsus and Ozempic tablets label tells patients to take one tablet once daily on an empty stomach in the morning with water, up to 4 ounces, and not with other liquids. It adds: swallow tablets whole, do not split, crush, chew or dissolve them in any solution, and wait at least 30 minutes after taking a tablet before eating, drinking or taking other oral medications. A missed dose is skipped, and the next dose is taken the following day. The Wegovy label gives the same empty-stomach, morning, up to 4 ounces of water wording for its tablets.
How much semaglutide reaches the blood
The label describes a co-formulation with SNAC, which facilitates absorption of semaglutide after oral administration, mainly in the stomach. Estimated absolute bioavailability is approximately 0.4% to 1% for Rybelsus 3 mg, 7 mg and 14 mg, and 1% to 2% for the Ozempic tablets 1.5 mg, 4 mg and 9 mg. The same label reports no clinically significant difference in steady-state exposure between Rybelsus 3, 7 and 14 mg and Ozempic tablets 1.5, 4 and 9 mg respectively, which is why the two sets of strengths pair up.
Labelled dose schedules for the tablets
These are the schedules printed on the labels, shown as published facts and not as advice. Each starts with a month on a dose that the label says is there for tolerability, then steps up.
| Product | Days 1 to 30 | Days 31 to 60 | Later options in the label |
|---|---|---|---|
| Rybelsus | 3 mg (label: not effective for glycemic control) | 7 mg | 7 mg maintained, or increased to 14 mg |
| Ozempic tablets | 1.5 mg (label: not effective for glycemic control) | 4 mg | 4 mg maintained, or increased to 9 mg |
| Wegovy tablets | 1.5 mg | 4 mg | 9 mg on days 61 through 90, then 25 mg from day 91 |
| Foundayo | 0.8 mg | 2.5 mg after at least 30 days | 5.5 mg after at least 30 days on 2.5 mg, then 9, 14.5 or 17.2 mg after at least 30 days on the current dose |
The Rybelsus and Ozempic tablets label states that the two products are not substitutable on a mg-to-mg basis. Its switching section also tells prescribers that a patient on the 0.5 mg Ozempic injection who moves to tablets starts one week after the last injection, at 7 mg or 14 mg of Rybelsus, or 4 mg or 9 mg of Ozempic tablets.
Foundayo: no fasting window on the label
The Foundayo label says to take it orally once daily, with or without food, and to swallow tablets whole without breaking, crushing or chewing. The cached label reports a geometric mean absolute bioavailability of 77% after a 0.8 mg dose. That is the practical difference with oral semaglutide, whose label estimates are 0.4% to 2%.
Pill versus injection: what changes
The Ozempic injection label says it is given once weekly, on the same day each week, at any time of day, with or without meals, into the abdomen, thigh or upper arm. The Ozempic pens deliver fixed doses: 0.25 mg or 0.5 mg increments from the 2 mg/3 mL pen, 1 mg from the 4 mg/3 mL pen and 2 mg from the 8 mg/3 mL pen. The Wegovy injection label lists doses from 0.25 mg up to 2.4 mg, plus a 7.2 mg strength.
So a weekly injected dose of around 1 mg and a daily tablet of 14 mg are different numbers, and the label reports that only a small share of oral semaglutide is absorbed. The labels do not offer a conversion formula, and the Wegovy label tells prescribers that if a patient does not tolerate the 25 mg tablet maintenance dosage, they can consider switching to the Wegovy injection at 1.7 mg once weekly. For the oral semaglutide evidence in more detail, see semaglutide in oral form.
Safety wording shared by the pill labels
- The Foundayo and Wegovy labels open with a boxed warning on the risk of thyroid C-cell tumors, and Foundayo is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
- The Rybelsus and Ozempic tablets label reports rare postmarketing cases of pulmonary aspiration in people having elective surgery or procedures under general anesthesia or deep sedation, and says available data are insufficient to recommend how to mitigate it.
- In the Rybelsus and Ozempic tablets label, gastrointestinal adverse reactions occurred in 41% of patients on the 14 mg tablet, 32% on the 7 mg tablet and 21% on placebo in the pooled placebo-controlled trials. Discontinuation for gastrointestinal reasons was 8%, 4% and 1%.
Common questions
Is there a GLP-1 pill?
Yes. Rybelsus, Ozempic tablets and Wegovy tablets are oral semaglutide, and Foundayo is oral orforglipron. Each has its own FDA label with its own indication, strengths and administration instructions.
Do GLP-1 pills work as well as the injections?
This page does not rank them. Each label reports results from its own trials, and the labels do not state a head-to-head conclusion. The tablets are not substitutable with injections on a mg-to-mg basis.
Can oral semaglutide be taken with food?
The label says no. The Rybelsus and Ozempic tablets label directs patients to take it on an empty stomach in the morning with up to 4 ounces of plain water and to wait at least 30 minutes before eating, drinking or taking other oral medications. The Foundayo label, by contrast, says with or without food.
Why are the tablet doses so much larger than the injected doses?
The labels report that only a small share of oral semaglutide is absorbed, with estimated bioavailability of 0.4% to 2%. The tablet strengths are listed in milligrams for a daily tablet, the injection doses in milligrams for a weekly injection, and the labels give no conversion between them.
Keep going
- Oral semaglutideRoute-specific evidence
- OrforglipronFoundayo's active ingredient
- Peptide injections guideWhat injectable labels say
- GLP-1 pipelineDrugs in development
- Peptide legal statusWhat is approved
- How to reconstitute peptides: the math, step by stepGuide · Reconstitution
- Bacteriostatic water: what it is and how it differs from sterile waterGuide · Diluents
- How to read an insulin syringe: units, mL and tick marksGuide · Syringes
- What are peptides? A plain-English guideGuide · Basics
Sources
- 1RYBELSUS and OZEMPIC tablets (semaglutide), prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Novo Nordisk label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 2FOUNDAYO (orforglipron) tablets, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3OZEMPIC (semaglutide) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Novo Nordisk label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 4WEGOVY (semaglutide) injection and tablets, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Novo Nordisk label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.